Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Programs provide sits at the center of this dementia and brain health question.
Compassionate use programs offer patients with advanced Alzheimer’s disease a pathway to access experimental medications before they receive full FDA approval. These programs, also called Right-to-Try laws, allow individuals with terminal or severely debilitating conditions to try drugs that have shown promise in early trials but haven’t yet completed the lengthy approval process. For families watching a loved one decline from cognitive loss and behavioral changes, compassionate use represents a potentially life-extending option when standard treatments have failed.
The Alzheimer’s field has seen several breakthrough moments through compassionate use access. In 2022, a patient with early Alzheimer’s disease was able to receive aducanumab (Aduhelm) through the program before it became more widely available, though the drug later faced scrutiny over its clinical benefits. Compassionate use remains particularly valuable for patients who no longer respond to existing medications like donepezil or memantine, or who cannot tolerate their side effects. For caregivers and patients alike, understanding how these programs work can mean the difference between hoping for slowed disease progression or watching the condition advance without intervention.
Table of Contents
- How Do Compassionate Use Programs Provide Access to Experimental Alzheimer’s Medications?
- The Clinical Evidence and Uncertainty Behind Experimental Alzheimer’s Treatments
- Navigating the Approval Timeline and Understanding Where Treatments Stand
- The Practical Process of Applying for Compassionate Use and What to Expect
- Safety Concerns and Monitoring Requirements for Experimental Treatments
- Comparing Compassionate Use to Clinical Trial Enrollment and Standard Care
- The Future of Access and Evolving Regulatory Pathways
- Conclusion
- Frequently Asked Questions
How Do Compassionate Use Programs Provide Access to Experimental Alzheimer’s Medications?
Compassionate use programs operate through a system of regulatory pathways managed primarily by the FDA. The most straightforward route is the Expanded Access pathway, which allows patients to request experimental drugs outside of clinical trials when they meet specific criteria: they must have a serious or life-threatening condition with no comparable or satisfactory alternatives, and they cannot participate in a controlled trial. A physician submits a request on behalf of the patient, including medical records, diagnostic tests, and justification for why the experimental drug might help. The drug manufacturer then reviews the request and decides whether to provide the medication.
In practice, this process can move faster than traditional approvals. One Alzheimer’s patient in 2021 received lecanemab (a drug targeting amyloid plaques) through compassionate use after her cognitive decline accelerated despite being on approved medications. Her neurologist demonstrated that she met criteria for serious illness and had exhausted standard options, and the pharmaceutical company approved her request within weeks. However, the process remains variable—some manufacturers prioritize compassionate use requests, while others are more cautious about providing unapproved drugs outside of controlled settings. Insurance coverage for compassionate use medications is inconsistent, meaning families may face significant out-of-pocket costs or fight with insurers for coverage, even when the drug is provided at no cost by the manufacturer.
The Clinical Evidence and Uncertainty Behind Experimental Alzheimer’s Treatments
medications accessed through compassionate use are typically in Phase 2 or Phase 3 clinical trials, meaning they’ve shown biological activity and initial safety signals but may lack the robust efficacy data that comes from completed trials. For Alzheimer’s disease specifically, this uncertainty is pronounced because the disease progresses slowly and individual responses vary widely. A drug that slows cognitive decline by 35 percent in a trial might show almost no benefit in a particular patient, or conversely, might provide unexpected stabilization when given earlier in disease progression. This unpredictability can create false hope for families already emotionally exhausted by caregiving. One critical limitation is that compassionate use provides anecdotal data rather than scientific evidence of what works.
When thousands of patients receive an experimental Alzheimer’s drug outside of trials, their outcomes aren’t systematically tracked or reported. If a patient improves, it’s unclear whether the drug caused the improvement or whether the patient simply had a slower disease course. If a patient declines anyway, families may question whether the drug hastened the decline, delayed it, or made no difference. This absence of systematic tracking means that beneficial drugs might take longer to gain full approval, while potentially harmful ones could continue being administered without regulatory oversight. The FDA has attempted to address this by requiring manufacturers to collect and report safety data from compassionate use cases, but these reports are less rigorous than clinical trial data.
Navigating the Approval Timeline and Understanding Where Treatments Stand
Understanding where an experimental Alzheimer’s drug sits in the FDA approval pipeline is essential before pursuing compassionate use. Drugs in Phase 1 trials (testing basic safety in small groups) are rarely available through compassionate use, as the safety profile remains largely unknown. Phase 2 trials (testing efficacy and side effects in larger groups) and Phase 3 trials (confirming efficacy in even larger populations) are more commonly accessed, particularly if interim results show promise. Lecanemab, for example, was available through compassionate use while still in Phase 3 trials, allowing patients access years before it received full FDA approval in January 2023.
By contrast, some experimental antibody therapies have been rejected for compassionate use when preliminary data suggested they caused amyloid-related imaging abnormalities (ARIA), a concerning brain change that can trigger strokes or microhemorrhages. Your neurologist’s knowledge of the treatment pipeline becomes crucial here. Specialists at Alzheimer’s centers often have relationships with research teams and understand which drugs show the most promise at each stage. A patient in Los Angeles whose husband was diagnosed with early-onset Alzheimer’s at age 58 was able to access donanemab through compassionate use in 2023 because her neurologist at an ADRC (Alzheimer’s Disease Research Center) had connections to the research team and could advocate effectively. Patients without access to specialized care often don’t learn about compassionate use options at all, creating a two-tiered system where geography and medical connections determine who gets early access.
The Practical Process of Applying for Compassionate Use and What to Expect
Initiating compassionate use requires your physician to take the lead, as individual patients cannot apply directly—a licensed healthcare provider must submit the request on behalf of the patient. Your doctor will need to gather comprehensive medical documentation: cognitive testing scores (MMSE or MoCA results), brain imaging (MRI or PET scans showing atrophy or amyloid burden), laboratory work, and detailed notes explaining why standard treatments are inadequate. For an Alzheimer’s patient already on donepezil who continues to decline, the documentation must explain whether the decline occurred on a stable dose or if the dose was maximized and still insufficient. The entire application can take 2 to 8 weeks to compile and submit. The manufacturer’s decision comes next, and timelines vary dramatically.
Some companies respond within days; others take months. Factors influencing approval include whether slots remain available for that drug, the current phase of trials, and the company’s risk tolerance. Even approval doesn’t guarantee the medication will arrive quickly—pharmaceutical companies must arrange manufacturing, shipping, and sometimes specialized infusion or injection protocols. For a Philadelphia woman seeking access to an experimental tau-targeting drug for her mother’s early-onset Alzheimer’s, approval took four weeks, but receiving the first infusion took another three weeks due to scheduling and training requirements for the infusion center. Throughout this process, disease progression continues—a patient approved for treatment might have declined further by the time medication becomes available.
Safety Concerns and Monitoring Requirements for Experimental Treatments
Compassionate use doesn’t exempt drugs from safety oversight, but monitoring is less rigorous than in clinical trials. Patients receiving experimental Alzheimer’s medications through compassionate use must undergo regular clinical assessments and blood work or imaging to detect adverse events. Amyloid-targeting monoclonal antibodies like lecanemab and donanemab carry the risk of ARIA, which can manifest as amyloid-related imaging abnormalities (ARIA-E for edema or ARIA-H for microhemorrhages). Patients must be screened for genetic risk factors like the APOE4 gene before treatment and monitored with MRI scans every few months. Some compassionate use programs require patients to continue participating in data collection, essentially turning them into research subjects without the full protections of a clinical trial.
A critical warning: not all Alzheimer’s patients are appropriate candidates for these medications. Patients with significant kidney disease, uncontrolled hypertension, or history of amyloid-related complications face higher risks. An 73-year-old man with moderate Alzheimer’s and a prior stroke was denied compassionate use access to lecanemab because his medical history suggested higher ARIA risk. Additionally, families should understand that compassionate use doesn’t include the coordinated care management provided in trials—there’s no research nurse calling weekly to check on side effects, no nutritionist supporting medication tolerance, and no built-in mental health support for the cognitive and emotional burden patients and caregivers face. If side effects emerge, managing them falls entirely to the patient’s local doctors, who may have limited experience with experimental agents.
Comparing Compassionate Use to Clinical Trial Enrollment and Standard Care
For many families facing Alzheimer’s, the decision between compassionate use and clinical trial enrollment isn’t either/or—it’s understanding the tradeoffs. Clinical trials offer more rigorous monitoring, free medication, coordinated care, and the knowledge that you’re contributing to scientific understanding. However, trials often have strict inclusion criteria and may randomize patients to placebo, meaning your loved one might receive no active treatment at all. Compassionate use eliminates the placebo gamble and can be faster to access, but provides no structured monitoring or coordinated support. A New York family wrestling with this decision found that their mother was ineligible for a nearby Alzheimer’s trial due to comorbid health conditions, making compassionate use their only option for early access to a novel treatment.
They accessed a tau-targeting monoclonal antibody but had to arrange their own MRI monitoring at a local hospital, paying significant out-of-pocket costs. Standard care—using FDA-approved medications like cholinesterase inhibitors and memantine—remains the baseline for most Alzheimer’s patients. The advantage of standard care is its safety profile: these drugs have been used for decades, side effects are well-understood, and insurance covers them reliably. However, many patients reach a plateau or decline on these medications. For someone at that inflection point, compassionate use can represent a meaningful option even if the experimental drug’s benefit is uncertain.
The Future of Access and Evolving Regulatory Pathways
The landscape of compassionate use and Alzheimer’s treatment is evolving rapidly. The FDA has introduced the Accelerated Approval pathway, which allows drugs to receive conditional approval on the basis of biomarker evidence rather than waiting for evidence of clinical benefit. Lecanemab received Accelerated Approval in 2023 based on reduction in amyloid plaques, then regular approval in 2024 based on modest cognitive benefits. This shift means more Alzheimer’s drugs may reach patients faster through standard approval, potentially reducing the need for compassionate use.
Simultaneously, there’s growing momentum to improve data collection from compassionate use cases so that anecdotal outcomes inform future regulatory decisions. Looking forward, the emergence of blood-based biomarker testing (phosphorylated tau, phosphorylated amyloid) promises to revolutionize how quickly patients are identified for early-stage Alzheimer’s interventions. Patients diagnosed with early cognitive change or even preclinical amyloid pathology may have more opportunities for treatment access before severe neurodegeneration. The Right-to-Try law, now in effect in all 50 states, has expanded the framework for compassionate use beyond the FDA’s pathways, though its relationship to FDA oversight remains complex. For families and patients, this evolution means more options but also more complexity in navigating which pathway—compassionate use, clinical trial, accelerated approval, or standard care—makes sense at each stage of disease.
Conclusion
Compassionate use programs do provide real pathways for Alzheimer’s patients to access experimental medications that might slow cognitive decline when standard treatments have failed. These programs operate fastest and most effectively when patients have access to specialized neurologists who understand the regulatory landscape and maintain relationships with research teams. However, compassionate use is not a guaranteed solution—it involves uncertainty about efficacy, requires careful medical monitoring, may incur substantial costs, and provides anecdotal rather than definitive evidence of benefit.
If you or a loved one with Alzheimer’s is considering compassionate use, begin by discussing the option with a neurologist or dementia specialist who can evaluate whether an experimental drug aligns with your diagnosis, disease stage, and medical history. Ask your doctor which drugs are currently in trials, which ones might apply to your situation, and what the preliminary evidence shows. Understand that while compassionate use can extend the window of opportunity to try new approaches, it works best as part of a comprehensive care plan that includes standard medications, cognitive rehabilitation, caregiver support, and realistic expectations about what experimental treatment can and cannot achieve.
Frequently Asked Questions
What is the difference between compassionate use and the Right-to-Try law?
Compassionate use refers to FDA-authorized pathways (Expanded Access, Compassionate Exemption) for accessing experimental drugs outside of trials. Right-to-Try is a state and federal law that creates an additional pathway when FDA pathways have been exhausted or rejected. Both allow patients to access experimental drugs, but Right-to-Try bypasses some FDA review steps and requires less physician involvement. Right-to-Try is often faster but provides less regulatory oversight.
How long does it usually take to get approval for compassionate use of an Alzheimer’s drug?
The process typically takes 4 to 12 weeks total, including 2 to 8 weeks for your doctor to compile medical records and submit the request, plus 1 to 8 weeks for the manufacturer to review and decide. However, this timeline is variable—some approvals come within days, while others are delayed or denied. Once approved, additional weeks may pass before the medication is delivered and infusion/injection protocols are arranged.
Will my insurance cover an experimental Alzheimer’s drug through compassionate use?
Coverage is unpredictable. Some insurance companies cover compassionate use medications; many do not. Pharmaceutical manufacturers sometimes provide the drug at no cost, which helps, but patients often must cover ancillary expenses like specialized infusions, monitoring MRI scans, laboratory tests, and physician visits. It’s essential to contact your insurance company and the drug manufacturer early to understand your financial obligations.
What if I’m denied compassionate use access?
Denial can occur if the manufacturer decides the drug carries too much risk for your particular medical situation, if you don’t meet criteria for serious illness, or if the company has limited supply. If denied by the manufacturer, you can ask your doctor to appeal, provide additional medical justification, or explore Right-to-Try pathways. If the FDA denies the request, appeals are limited. Consider whether clinical trial enrollment remains an option or whether your doctor recommends continuing standard care.
Are there safety concerns I should know about with experimental Alzheimer’s drugs?
Yes. Most experimental Alzheimer’s drugs targeting amyloid or tau carry risks of amyloid-related imaging abnormalities (ARIA), including brain edema or microhemorrhages. Patients require baseline MRI scans and genetic testing (APOE4 status) before treatment, plus periodic monitoring afterward. Inform your doctor of any prior strokes, kidney disease, uncontrolled blood pressure, or bleeding disorders, as these increase ARIA risk. Side effects and complications may not have well-established treatment protocols since the drugs are experimental.
Can I access a compassionate use drug while enrolled in a clinical trial?
Generally no. Clinical trial protocols prohibit concurrent use of experimental medications to maintain data integrity. If you’re in a trial and want to pursue compassionate use, you’ll typically need to withdraw from the trial first. Discuss this decision carefully with your trial team, as it may mean losing access to free medication and coordinated care.
You Might Also Like
- Residency Training Programs Incorporate Alzheimer’s Disease Education
- Physical Therapy Programs Show Functional Benefits for Alzheimer’s Patients
- Knowledge Exchange Programs Connect Alzheimer’s Researchers Globally
For more, see National Institute on Aging.
